Menopausal-type symptoms in young breast cancer survivors
Menopausal-type symptoms in young breast cancer survivors
复制标题
DOI：
10.1093/annonc/mdl299
复制
发表时间：
2006-12-01
影响因子：
50.5
通讯作者：
Partridge, A. H.
中科院分区：
文献类型：
--
作者：
Leining, M. G.;Gelber, S.;Partridge, A. H.
背景：之前关于非常年轻的乳腺癌幸存者的更年期症状的信息很少。方法：我们与青年生存联盟合作，使用来自乳腺癌预防试验症状清单的项目，对 40 岁或以下有乳腺癌病史的女性进行了一项基于互联网的调查。结果：共有 371 名受访者符合分析资格。诊断时的平均年龄为 32.8 岁，随访时的平均年龄为 36.2 岁； 89% 的女性接受化疗，49% 接受他莫昔芬，15% 接受卵巢抑制，4% 接受芳香酶抑制剂。在调查时，37% 的人正在服用他莫昔芬，9% 的人正在服用卵巢抑制药物。排除卵巢抑制的女性，77%的女性在随访时处于绝经前状态。许多女性报告了令人烦恼的更年期症状。特别是，46% 的女性报告潮热，39% 的女性报告性交困难。在症状评分的线性回归模型中，当前卵巢抑制、绝经后状态、诊断前的基线焦虑、诊断后怀孕、既往化疗和较低的财务状况与更令人烦恼的症状相关。结论：大量年轻乳腺癌幸存者经历令人烦恼的更年期症状。虽然对我们的调查做出回应的女性可能代表了一组经过挑选的幸存者，但这些发现可能对患有乳腺癌的年轻女性的治疗决策和长期生活质量产生重要影响。
Background: There has been little previous information available about menopausal-type symptoms in very young breast cancer survivors.Methods: In collaboration with the Young Survival Coalition, we conducted an Internet-based survey of women with a history of breast cancer diagnosed at age 40 years or younger using items derived from the Breast Cancer Prevention Trial symptom checklist.Results: A total of 371 respondents were eligible for analysis. Mean age at diagnosis was 32.8 years and mean age at follow-up 36.2 years; 89% of women received chemotherapy, 49% tamoxifen, 15% ovarian suppression, 4% aromatase inhibitors. At the time of survey, 37% were taking tamoxifen and 9% ovarian suppression. Excluding women on ovarian suppression, 77% of women were premenopausal at follow-up. Many women reported bothersome menopausal-type symptoms. In particular, 46% of women reported hot flashes and 39% reported dyspareunia. In a linear regression model of symptom scores, current ovarian suppression, postmenopausal status, baseline anxiety before the diagnosis, pregnancy after the diagnosis, prior chemotherapy, and lower perceived financial status were associated with more bothersome symptoms.Conclusion: A substantial number of young breast cancer survivors experience bothersome menopausal symptoms. While the women who responded to our survey may represent a select group of survivors, these findings may have important implications for treatment decision making and long-term quality of life of young women with breast cancer.